Patents Assigned to RLL, LLC
  • Anticancer therapeutic agents
    Patent number: 10420840
    Abstract: The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: September 24, 2019
    Assignee: RLL, LLC
    Inventors: Robert J. Hickey, Linda H. Malkas